REG - Cambridge Cognition - Automated quality assurance for clinical trials

Cambridge Cognition HoldingsAnnouncement

24/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231024:nRSX0261Ra&default-theme=true

RNS Number : 0261R  Cambridge Cognition Holdings PLC  24 October 2023

 

24 October 2023

Cambridge Cognition Holdings Plc

 

("Cambridge Cognition" or the "Company")

 

Launch of automated quality assurance for clinical trials

 

Cambridge Cognition (AIM: COG), which develops and markets digital solutions
to assess brain health, is pleased to announce the launch today of AQUA, the
Company's automated quality assurance solution for central nervous system
("CNS") clinical trials that is powered by the Company's innovative
Winterlight speech and language platform.  This is the first such solution
available in the market. The Company has already secured one customer for
AQUA.

 

Cambridge Cognition believes there is considerable potential for AQUA.  Based
on independent market research commissioned by the Company, the market
opportunity for automated quality assurance for CNS clinical trials measuring
cognition alone is estimated to be £16m per annum within five years.
Cambridge Cognition also believes there could be further opportunities for use
of the technology in other therapeutic areas and in healthcare applications.

 

Quality assurance is an essential requirement for clinical trials as set out
under 'Good Clinical Practice' guidelines. CNS clinical trials, for example
for Alzheimer's disease or Schizophrenia, can rely on a clinician asking a
patient questions and manually scoring the answer.  In later stage, large
clinical trials, quality assurance is critical as poor quality clinical
consultations could change the result of the trial.  Currently, expert
clinicians usually listen to a proportion of patient consultations for later
stage clinical trials to identify and report mistakes.  Those reviews can be
slow and expensive.

 

AQUA was developed by the Company using advanced voice technology developed by
Winterlight to conduct quality assurance more quickly, economically and
accurately.  AQUA can be used to assess every single patient consultation and
provide a structured report to the pharmaceutical company within hours, not
days or weeks.  The product is available in nine languages and is available
for several widely-used CNS clinical instruments and adaptable for almost all.
 AQUA can also confirm that it is the same patient in each subsequent
consultation.

 

With AQUA, pharmaceutical companies can be more confident that the data from
their clinical trials is accurate.  They can address problems, such as
off-script questioning or inaccurate scoring, with a particular clinical trial
site within hours.  Then subsequently, they have reports from every single
patient consultation as evidence of appropriate quality adherence for
regulators for a new drug application.

 

The Company has conducted its own trial comparing non-experts using AQUA with
expert clinicians, showing that there was a high degree of correlation.
Using these results, the Company has already secured a lead customer for AQUA
and the solution will be used for the first time in a phase II clinical trial
for Alzheimer's disease that is starting later in 2023.

 

Commenting, Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:

"AQUA is an entirely new solution for the clinical trials market providing a
level of quality assurance that was not possible before, from a cost or time
perspective, with traditional reviews by medical experts.  We acquired
Winterlight Labs intending to commercialise their innovative verbal clinical
assessments and, by launching AQUA, we have achieved the first of our product
goals.  We are also really pleased to have already won a client for AQUA as
we expect this will provide us with an excellent case study for future sales."

 

 

For further information, contact:

 

 Cambridge Cognition Holdings Plc                      Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer
 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)  Tel: 020 7886 2968

 Freddy Crossley / Emma Earl                           (Corporate Finance)

 Rupert Dearden                                        (Corporate Broking)
 Dowgate Capital Limited (Joint Broker)                Tel: 020 3903 7715

 David Poutney / James Serjeant
 IFC Advisory Ltd (Financial PR and IR)                Tel: 020 3934 6630

 Tim Metcalfe / Graham Herring / Zach Cohen

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit www.cambridgecognition.com
(http://www.cambridgecognition.com)

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBIBDGDBDDGXX